NCT06644170View on ClinicalTrials.gov

A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid Neoplasm
Interventions
BEHAVIORAL

Behavioral Intervention

Attend individual visits

BEHAVIORAL

Group Therapy

Attend group visits

DRUG

Psilocybin

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Steven & Alexandra Cohen Foundation

OTHER

lead

University of Washington

OTHER

NCT06644170 - A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | Biotech Hunter | Biotech Hunter